$7.38
3.47%
Nasdaq, Apr 21, 08:47 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Stock price

$7.64
-2.48 24.51% 1M
-15.69 67.25% 6M
-6.07 44.27% YTD
-11.00 59.01% 1Y
-15.56 67.07% 3Y
-7.36 49.07% 5Y
-27.70 78.38% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.27 3.41%
ISIN
US62855J1043
Symbol
MYGN
Sector
Industry

Key metrics

Market capitalization $704.19m
Enterprise Value $733.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.88
P/S ratio (TTM) P/S ratio 0.84
P/B ratio (TTM) P/B ratio 0.99
Revenue growth (TTM) Revenue growth 11.21%
Revenue (TTM) Revenue $837.60m
EBIT (operating result TTM) EBIT $-89.20m
Free Cash Flow (TTM) Free Cash Flow $-27.70m
Cash position $111.00m
EPS (TTM) EPS $-1.40
P/E forward negative
P/S forward 0.83
EV/Sales forward 0.87
Short interest 8.21%
Show more

Is Myriad Genetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Myriad Genetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Myriad Genetics, Inc. forecast:

7x Buy
41%
6x Hold
35%
4x Sell
24%

Analyst Opinions

17 Analysts have issued a Myriad Genetics, Inc. forecast:

Buy
41%
Hold
35%
Sell
24%

Financial data from Myriad Genetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
838 838
11% 11%
100%
- Direct Costs 284 284
2% 2%
34%
554 554
17% 17%
66%
- Selling and Administrative Expenses 472 472
2% 2%
56%
- Research and Development Expense 110 110
24% 24%
13%
-28 -28
62% 62%
-3%
- Depreciation and Amortization 61 61
14% 14%
7%
EBIT (Operating Income) EBIT -89 -89
39% 39%
-11%
Net Profit -127 -127
52% 52%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Myriad Genetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Myriad Genetics, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units e...
Neutral
GlobeNewsWire
14 days ago
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnell...
Positive
Schaeffers Research
about one month ago
Medical equipment stock Myriad Genetics Inc (NASDAQ:MYGN) was last seen up 9.8% at $11.25, after an upgrade from Piper Sandler to "overweight" from "neutral," with a price-target hike to $12.50 from $11.50.
More Myriad Genetics, Inc. News

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Paul Diaz
Employees 2,700
Founded 1991
Website www.myriad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today